

## SCHEDA N. 1

*Argomento:* “ Farmacologia in ambito oncologico”

### **Domanda 1**

Descrivere brevemente la farmacologia degli alcaloidi della vinca

*Argomento:* “ Conoscenza Tecnologie applicate agli studi farmacologici”

### **Domanda 2**

Descrivere brevemente la tecnologia MULTIPLEX

*Argomento:* “ Statuto dell’Università”

### **Domanda 3**

Quali sono le principali funzioni del Direttore del Dipartimento?

*Software*

### **Domanda 4**

Quali sono le principali funzionalità di EXCEL?

*Inglese*

### **Domanda 5**

Fluorouracil (FU) and its oral prodrugs, capecitabine and tegafur, are the backbone of numerous combination regimens for the treatment of solid neoplasms, despite severe-to-fatal toxicities associated with their administration. The cause for the adverse drug reactions was often found in the reduction or the lack of dihydropyrimidine dehydrogenase (DPD) activity because of *DPYD* gene allelic variants.<sup>1</sup> Several studies

## SCHEDA N. 2

*Argomento:* “ Farmacologia in ambito oncologico”

### **Domanda 1**

Descrivere brevemente la farmacologia dei Tassani

*Argomento:* “ Conoscenza Tecnologie applicate agli studi farmacologici”

### **Domanda 2**

Descrivere brevemente la tecnologia real-time PCR

*Argomento:* “ Statuto dell’Università”

### **Domanda 3**

Quali sono le attività istituzionali dell’Università?

*Software*

### **Domanda 4**

In cosa consiste l’operazione di back-up di dati?

*Inglese*

### **Domanda 5**

For some authors, the analysis of *DPYD* variants alone is only moderately predictive of DPD deficiency. Therefore, DPD phenotyping, such as the dihydrouracil:uracil ratio, could be considered the most appropriate method to screen for DPD deficiency, either on its own or in association with genotyping.<sup>3</sup> However, in recent years, the genetic analysis of *DPYD* allelic variants took place until recommendations from the European Medicines Agency (EMA) advised performing genetic tests on all patients who are candidates for fluoropyrimidines.<sup>4</sup> The

## SCHEDA N. 3

*Argomento:* “ Farmacologia in ambito oncologico”

### **Domanda 1**

Descrivere brevemente la farmacologia dei farmaci anti-vascular endothelial growth factor (VEGF)

*Argomento:* “ Conoscenza Tecnologie applicate agli studi farmacologici”

### **Domanda 2**

Descrivere brevemente le principali procedure di colture cellulari in farmacologia

*Argomento:* “ Statuto dell’Università”

### **Domanda 3**

Quali sono le principali funzioni del Direttore Generale?

*Software*

### **Domanda 4**

Quali sono le combinazioni rapide da tastiera per i comandi Copia, Taglia e Incolla?

*Inglese*

### **Domanda 5**

As demonstrated by Schwab et al,<sup>7</sup> *DPYD* genetic variants are one of many factors that may influence fluoropyrimidine tolerability. Besides the presence of *DPYD* alleles with reduced enzyme activity, female sex, folate intake, and a higher rate of drug infusion may also increase the risk of toxicities. These characteristics may explain how pharmacogenetic tests of *DPYD* cannot prevent all toxicities, as Innocenti et al<sup>2</sup> stress in their discussion of the specificity and sensitivity of DPD genetic testing. Thus, the performance

## SCHEDA N. 4

*Argomento:* “ Farmacologia in ambito oncologico”

### **Domanda 1**

Descrivere brevemente la farmacologia della chemioterapia metronomica

*Argomento:* “ Conoscenza Tecnologie applicate agli studi farmacologici”

### **Domanda 2**

Descrivere brevemente la tecnologia ELISA

*Argomento:* “ Statuto dell’Università”

### **Domanda 3**

Quali sono le funzioni principali del Rettore?

*Software*

### **Domanda 4**

Qual è la differenza tra hardware e software?

*Inglese*

### **Domanda 5**

The issue of severe-to-fatal toxicities associated with fluoropyrimidine administration has an indissoluble bond with another question relevant to treatment efficacy. Although the noninferior efficacy of a reduced dosage of FU has been shown in patients with colorectal cancer and *DPYD* allelic variants in a randomized prospective clinical trial,<sup>10</sup> no similar data are available for other tumor types such as breast or head and neck cancer. Moreover, if a reduced starting FU